The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density.

Inclusion Criteria: * Two or more ground-glass lesions (pure ground glass or partially solid) presented in the CT scan of lung that cannot be operated simultaneously * There was at least one lung cancer lesion with a diameter of 1-3cm confirmed pathologically or by multidisciplinary team. * Excluding lymph nodes and distant metastasis through imaging * ECOG PS 0-1 * Vital organ functions meet the following requirements: 1)The absolute count of neutrophils ≥1.5×109/L 2)Platelet ≥90×109/L 3)Hemoglobin ≥9g/dL 4)Serum albumin ≥3g/dL 5)Thyroid stimulating hormone (TSH) ≤ULN (if abnormal, T3 and T4 levels should be examined at the same time; if T3 and T4 levels are normal, they can be included in the group) 6)Bilirubin ≤ULN 7)ALT and AST≤1.5 ULN 8)AKP≤ 2.5ULN or less 9)Serum creatinine ≤1.5 ULN or creatinine clearance ≥60mL/min * Subjects volunteered to participate in this study and signed informed consent, with good compliance. Exclusion Criteria: * Non-calcified lesions with diameter more than 3mm are presented * The presence of any active autoimmune diseases or a history of autoimmune diseases * Those who have used other drugs in clinical study within 4 weeks before the first time of drug use * Severe allergic reaction to monoclonal antibody * Heart clinical symptoms or diseases are not well controlled * Subjects with congenital or acquired immune deficiency (such as HIV infection) or active hepatitis * According to the researcher's judgment, the subjects have other factors that may lead to the forced termination of this study